Year: 2021

Approved protocol amendment enables enrollment of ATTR-CM patients in the ongoing first-in-human study of NTLA-2001, a systemically delivered CRISPR/Cas9-based therapy CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) —  Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced today that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has approved a protocol amendment for the Company’s ongoing Phase 1 study of NTLA-2001 to include patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). The study of NTLA-2001 now includes patients with ATTR-CM to be enrolled in new dose-escalation and expansion cohorts. The inclusion of the ATTR-CM patient population is in addition to the original Phase 1 study population, which is currently evaluating NTLA-2001 in patients with ATTR amyloidosis with polyneuropathy...

Retail & Consumer Products Practice Revises 2021 U.S. Online Retail Sales Forecast to $873 Billion, a 14.9% Year-Over-Year Increase from 2020 WASHINGTON, Nov. 22, 2021 (GLOBE NEWSWIRE) — Despite strong retail sales to date in 2021 and wide expectations of robust holiday spending, consumers have become more cautious in their spending intentions as the all-important holiday season approaches, according to a new report released today by FTI Consulting, Inc. (NYSE: FCN). FTI Consulting’s 2021 Holiday Retail Report provides insight into the mindset of holiday shoppers this year, from changing preferences and shopping habits to economic trends as the U.S. continues to recover from the COVID-19 pandemic. The Retail & Consumer Products practice at FTI Consulting surveyed 600 consumers who spent at least $500 on holiday shopping...

CALGARY, Alberta, Nov. 22, 2021 (GLOBE NEWSWIRE) — (PIPE – TSX) Pipestone Energy Corp. (“Pipestone” or the “Company”) is pleased to announce the Toronto Stock Exchange (the “TSX”) has accepted the notice filed by the Company to implement a normal course issuer bid (the “NCIB”). The NCIB allows Pipestone to purchase up to 9,598,347 common shares (“Common Shares”), representing 5% of its 191,966,942 outstanding Common Shares as at November 12, 2021. The NCIB is scheduled to commence on November 25, 2021 and is due to expire no later than November 24, 2022. Under the NCIB, Common Shares may be repurchased in open market transactions on the TSX and other alternative trading platforms in Canada and in accordance with the rules of the TSX governing NCIB’s. The total number of Common Shares Pipestone is permitted to purchase is subject...

CINCINNATI, Nov. 22, 2021 (GLOBE NEWSWIRE) — Hillman Solutions Corp. (NASDAQ: HLMN), (“Hillman” or “the Company”), a leading hardware solutions company, today announced that the Company will redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), that were issued under the Amended and Restated Warrant Agreement (the “Warrant Agreement”), dated November 13, 2020, by and between the Company and Continental Stock Transfer & Trust Company (“CST”), as warrant agent (the “Warrant Agent”), as part of the units sold in the Company’s initial public offering (the “IPO”) and that remain outstanding at 5:00 p.m. New York City time on December 22, 2021 (the “Redemption Date”) for a redemption price of $0.10 per Public Warrant. In...

Interim pharmacokinetic, safety and tolerability, and preliminary efficacy data from Phase 1 dose escalation to be presented Company to host investor webcast at 8:30 a.m. ET on Wednesday, December 8, 2021SAN FRANCISCO, Nov. 22, 2021 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced two poster presentations on OP-1250, an investigational complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in development for the treatment of metastatic breast cancer and other women’s cancers, at the upcoming San Antonio Breast Cancer Symposium (SABCS) meeting being held December 7-10, 2021, at the Henry B. Gonzalez...

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, announced today that it has appointed Richard Gaynor, M.D., to its Board of Directors. Dr. Gaynor will also serve as Chair of the Research and Development Committee. Dr. Gaynor is the President and Chief of Research and Development of BioNTech US. Prior to this, he was President, Research and Development, at Neon Therapeutics, beginning in 2016. Previously, Dr. Gaynor spent 15 years in senior roles at Lilly Oncology, including as Senior Vice President, Clinical Development and Medical Affairs. He chaired the Lilly Oncology Research and Development Committee and helped oversee collaborations with such companies as Bristol Myers...

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced members of its management team will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference from Nov. 30-Dec. 2, 2021. The company’s pre-recorded fireside chat is available for registered attendees via the Piper Sandler conference site from Nov. 22-Dec. 2. An archived webcast of the fireside chat can be accessed via the “Events & Presentations” section of the company’s investor site at https://ir.monterosatx.com/. About Monte RosaMonte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader medicines. These medicines are designed to employ the body’s natural mechanisms to selectively...

Q3 Revenue up 111% Y/Y to $96.2 Million, up 5% sequentially Q3 Adjusted EBITDA of $26.0 million, up 40% Y/Y and down 5% sequentially as the Company Invests in Future Growth US GAAP Operating Loss of $8.9 Million Included Non-Cash, One-Time Expenses, and Non-Operating Adjustments totaling $34.9 Million Raised $50 Million in Cash with Early Call of Outstanding Warrants and $150 Million in Offering of Additional Senior Notes Company Provides Q4 2021 Guidance for over 10% Sequential Revenue Growth with Adjusted EBITDA Flat Sequentially Proposing to Add Two Dispensaries in Chicago with Announced Agreement to Acquire Dispensary 33, Which Would Increase Illinois Retail Footprint to Five Stores Revising 2022 Adjusted EBITDA Target to $250-300 Million, and Maintaining 2022 Revenue Target of $800 Million to Reflect Revised Timing for Capital Projects...